Skip to main content
Psychopharmacology Bulletin › All Volumes & Issues › VOL 52 No. 3
PSYCHOPHARMACOLOGY BULLETIN

VOL 52 No. 3

Articles in This Issue

ORIGINAL RESEARCH

Influence of CYP2C19*17 Genetic Polymorphism on the Steady-State Concentration of Escitalopram in Patients with Recurrent Depressive Disorder

MS Zastrozhin, VYu Skryabin, F Rwere, AE Petukhov, EP Pankratenko, SA Pozdniakov, VA Ivanchenko, VV Noskov, IA Zaytsev, NV Vinokurova, DS Horyaev, RV Vlasovskih, EA Bryun, DA Sychev
Escitalopram is commonly prescribed to patients with recurrent depressive disorder. Some of them do not show adequate response to treatment with escitalopram, while many of them experience adverse drug reactions. Objective: The objective of our...
Pages 8-19 Read Article
ORIGINAL RESEARCH

Lidocaine Ineffectiveness Suggests New Psychopharmacology Drug Target

Mark Mintz, Victor Badner, Lynn K. Feldman, Pnina Mintz, Mana Saraghi, Jonathan Diaz, Irina Mezhebovsky, Irene Axelrod, Joseph Gleeson, Chang Liu, Cathy Smith, Helen Chow, David Zurakowski, Michael M. Segal
The mechanism of many neuropsychiatric disorders remains unknown, but the ineffectiveness of the sodium channel blocker lidocaine has been suggested to be a biomarker for Attention Deficit Hyperactivity Disorder (ADHD) and a severe form of...
Pages 20-30 Read Article
ORIGINAL RESEARCH

Sleep Deprivation & Amphetamine Induced Psychosis

Amr Said Shalaby, Abdullah Osama Bahanan, Mishal Hasan Alshehri, Khaled Ahmed Elag
Objectives To explore the relationship between sleep deprivation and amphetamine-induced psychosis. Methods The patient group included 78 patients with a diagnosis of amphetamine (Captagon)-induced psychosis. The control group included 49 patients with no current or...
Pages 31-40 Read Article
EVIDENCE-BASED PSYCHIATRY

Combining Medication Adherence Support Plus Long-Acting Injectable Antipsychotic Medication: A Post-Hoc Analysis of 3 Pilot Studies

Thomas Canales, Samuel Rodman, Danette Conklin, Kaylee Sarna, Martha Sajatovic, Jennifer B Levin
Patients with severe mental illness (SMI) who do not adhere to treatment have a lower quality of life, with more hospitalizations, interpersonal relationship conflict, homelessness, substance use problems, and incarceration compared to patients who adhere...
Pages 41-57 Read Article
DRUG DISPOSITION & PHARMACOKINETICS

Correlation of 1846G>A Polymorphism of CYP2D6 Gene with Haloperidol Efficacy and Safety in Patients with Alcoholic Hallucinoses

AA Parkhomenko, MS Zastrozhin, VYu Skryabin, VA Ivanchenko, SA Pozdniakov, VV Noskov, IA Zaytsev, NP Denisenko, KA Akmalova, EA Bryun, DA Sychev
Previous studies have shown that haloperidol biotransformation occurs with participation of the CYP2D6 isoenzyme. The CYP2D6 gene is highly polymorphic, which may contribute to differences in its activity and in the haloperidol biotransformation rates across...
Pages 58-67 Read Article
COMPLICATED CASE HISTORY

New-Onset Psychotic Symptoms Following Abrupt Buprenorphine/ Naloxone Discontinuation in a Female Patient with Bipolar Disorder: A Case Report

Yezhe Lin, Alexander D Zhang, Ching-Fang Sun, Justin B White, Ansi Qi, Jessica A Farrell, Robert L Trestman, Rachel K Martin, Anita S Kablinger
Buprenorphine and naloxone (Suboxone) is a combination medication-assisted treatment (MAT) for opioid use disorder. MAT withdrawal-induced psychosis is a rare clinical presentation. To our best knowledge, only three reports have summarized the characteristic manifestations of...
Pages 72-80 Read Article